ExpreS2ion Biotechnologies - Combination testing and site expansion approved ahead of schedule
30 juni, 15:39
30 juni, 15:39
ExpreS2ion today announced that Austrian authorities have approved the company's protocol amendment to test its breast cancer immunotherapy candidate, ES2B-C001. The protocol amendment was originally expected to be approved in Q3 2025. However, the approval came ahead of schedule, supporting the current timeline and possibly indicating an unmet medical need in this indication.
30 juni, 15:39
ExpreS2ion today announced that Austrian authorities have approved the company's protocol amendment to test its breast cancer immunotherapy candidate, ES2B-C001. The protocol amendment was originally expected to be approved in Q3 2025. However, the approval came ahead of schedule, supporting the current timeline and possibly indicating an unmet medical need in this indication.
Börsen idag
Börsen idag
Börsen idag
Börsen idag
OMX Stockholm 30
1 DAG %
Senast
2 491,02